Since Thursday, a new exchange traded fund issued by WisdomTree is tradable on Xetra and Börse Frankfurt.
The WisdomTree BioRevolution UCITS ETF-USD Acc enables investors to invest in innovative genetics and biotechnology companies from the sectors of human health, agriculture and food as well as chemicals and energy, which benefit from the accelerating development of computing, automation, and artificial intelligence.
The index includes companies that develop new cures and therapies to combat genetic diseases or facilitate their diagnosis and early detection. The index also contains companies whose developments in the fields of food and agriculture address the problems of an increasingly growing world population. In addition, topics such as research into so-called brain-machine interfaces, which can help people with paralysis, among other things, are also included.
Companies that are not in line with the principles of the United Nations Global Compact, are involved in serious ESG-related controversies, or with significant business activities in the areas of thermal coal, weapons or tobacco are excluded from the index.
Accruing dividend income is reinvested.
|Name||Asset class||ISIN||On-going charges||Distribution policy||Reference index|
BioRevolution UCITS ETF – USD Acc
|Equity ETF||IE000O8KMPM1||0.45 per cent||Accumulating||WisdomTree BioRevolution ESG Screened Index|
The product offering in Deutsche Börse’s XTF segment currently comprises a total of 1,749 ETFs. With this selection and an average monthly trading volume of around €17 billion, Xetra is the leading trading venue for ETFs in Europe.